Mendel.ai Secures $35M Series B to Revolutionize Clinical Data Workflows with AI-Driven Hypergraph Technology

Mendel.ai is thrilled to announce a significant milestone in its journey toward revolutionizing healthcare technology with the recent raise of US$35,000,000. Headquartered in San Jose, California, this funding round further strengthens Mendel.ai’s mission to supercharge clinical data workflows by integrating large language models with its proprietary clinical hypergraph. This breakthrough approach empowers healthcare providers with scalable clinical reasoning that is both fast and reliable, ensuring that medical insights are delivered without hallucinations while maintaining 100% explainability. With a resolute focus on eliminating ambiguity and streamlining the complexities of clinical data, Mendel.ai is uniquely positioned to empower clinicians and researchers with precise, actionable data that can transform patient care and accelerate clinical decision-making. This latest round of funding not only solidifies Mendel.ai’s position in the burgeoning intersection of artificial intelligence and healthcare but also demonstrates the robust confidence of blue-chip investors such as Oak HC/FT and DCM. The capital infusion will be strategically deployed to refine its existing technology, further scale its operations, and expand its reach into new markets. The company is poised to explore additional applications that can harness the power of its innovative tools to bridge gaps in clinical data interpretation. With a dedicated team at the helm, Mendel.ai is committed to driving forward a future where precision in clinical reasoning becomes the standard, thereby improving patient outcomes and saving lives on a global scale. This milestone not only marks a pivotal moment in the company’s growth but also sets the stage for transformative advancements in the healthcare sector.